- Home
- TTGT vs BCYC Comparison
TTGT vs BCYC Comparison
Compare TTGT & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TTGT
- BCYC
- Stock Information
- Founded
- TTGT 1999
- BCYC 2009
- Country
- TTGT United States
- BCYC United Kingdom
- Employees
- TTGT N/A
- BCYC N/A
- Industry
- TTGT Telecommunications Equipment
- BCYC Biotechnology: Pharmaceutical Preparations
- Sector
- TTGT Telecommunications
- BCYC Health Care
- Exchange
- TTGT Nasdaq
- BCYC Nasdaq
- Market Cap
- TTGT 598.8M
- BCYC 566.5M
- IPO Year
- TTGT 2007
- BCYC 2019
- Fundamental
- Price
- TTGT $7.32
- BCYC $8.05
- Analyst Decision
- TTGT Buy
- BCYC Buy
- Analyst Count
- TTGT 6
- BCYC 10
- Target Price
- TTGT $19.33
- BCYC $25.00
- AVG Volume (30 Days)
- TTGT 539.5K
- BCYC 297.7K
- Earning Date
- TTGT 08-07-2025
- BCYC 08-05-2025
- Dividend Yield
- TTGT N/A
- BCYC N/A
- EPS Growth
- TTGT N/A
- BCYC N/A
- EPS
- TTGT N/A
- BCYC N/A
- Revenue
- TTGT $284,897,000.00
- BCYC $25,722,000.00
- Revenue This Year
- TTGT $76.52
- BCYC $7.35
- Revenue Next Year
- TTGT N/A
- BCYC N/A
- P/E Ratio
- TTGT N/A
- BCYC N/A
- Revenue Growth
- TTGT 13.01
- BCYC N/A
- 52 Week Low
- TTGT $6.49
- BCYC $6.10
- 52 Week High
- TTGT $33.08
- BCYC $28.67
- Technical
- Relative Strength Index (RSI)
- TTGT 50.56
- BCYC 55.72
- Support Level
- TTGT $6.49
- BCYC $7.06
- Resistance Level
- TTGT $7.37
- BCYC $8.12
- Average True Range (ATR)
- TTGT 0.46
- BCYC 0.40
- MACD
- TTGT 0.05
- BCYC 0.12
- Stochastic Oscillator
- TTGT 45.86
- BCYC 95.20
About TTGT TechTarget Inc.
TechTarget Inc is engaged in the business-to-business (B2B) accelerator, informing and influencing technology buyers and sellers. Through its B2B first-party data and an end-to-end portfolio of data-driven solutions, it services the full B2B product lifecycle for customers from, messaging, and content development to in-market activation via brand, demand generation, purchase intent data, and sales enablement from R&D to ROI.
About BCYC Bicycle Therapeutics plc
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.